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SummArY – Prostate cancer is responsible for the largest number of cancer-related deaths in 
male population in many countries of the world. Aggressive forms of the disease are associated with 
an increased risk of local recurrence and death. treatment of high-risk local prostate cancer most com-
monly involves radical prostatectomy (rP) or external beam radiation therapy (eBrt) combined 
with androgen deprivation therapy (Adt) with or without the addition of brachytherapy (Bt). The 
use of surgery for high risk prostatic carcinoma (hrPC) is on the rise, because of its advantages in-
cluding the possibility of cure with surgery alone without the risk of toxicities from prolonged Adt, 
accurate staging, and avoiding the influence of PSA originating from benign prostatic hyperplasia on 
future therapy. oligometastatic prostate cancer may be considered as the last border of possibly cur-
able disease. radical prostatectomy in oligometastatic prostate cancer can significantly decrease the 
risk of local complications but only multimodal approach in selected group of patients may offer op-
portunities to eradicate tumor or delay its progression. Surgery for oligometastatic disease most com-
monly targets lymphatic disease with salvage pelvic lymph node dissection, whereas it rarely targets 
distant metastases. further prospective, randomized studies are necessary to define the role and value 
of therapies in oligometastatic prostate cancer.
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Prostate cancer is, after skin malignancies, the sec-
ond most common malignant disease in male popula-
tion. Although it usually has an indolent course, “high-
risk” prostate cancer (hrPC) tends to recur despite 
optimal treatment and may have fatal outcome1.
The european Association of urology (eAu) de-
fines hrPC with specific criteria, including higher 
PSA levels of >20 ng/ml, or gleason score at biopsy of 
>7 (iSuP grade 4/5) or clinical stage t2c2. hrPC is 
associated with an increased risk for biochemical and 
metastatic progression and cancer-related death3. 
When the tumor is not fixed to the pelvic wall or does 
not invade the urethral sphincter, radical prostatecto-
my (rP) is considered as the first step for treatment3. 
other treatment options include eBrt with Adt or 
eBrt plus Bt and Adt. Advantages of rP for 
hrPC include accurate staging and grading, removal 
of benign source of PSA and possibly avoiding Adt4.
The comparative studies of different treatment 
strategies for hrPC have become a matter of intense 
debate. As shown in meta-analysis performed by Wal-
lis et al. on 118,300 patients, the risk of mortality, both 
overall and cancer-specific, was higher in patients 
treated with radiotherapy than in those who under-
went surgery5. Similarly, meta-analysis that included 
patients with only hrPC has shown higher survival 
rate among patients treated with surgery compared to 
those who were treated with radiotherapy6. A recent 
paper by Berg et al.7 showed that in young and healthy 
men presenting with hrPC, rP resulted with better 
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overall survival in comparison with combination of 
eBrt and Bt; hazard ratio (hr) erBt plus Bt:rP 
was 1.22.
gansler et al. reported that 58% of 6,303 patients 
with biopsy proven gleason score 8 were downgraded 
on final pathology after rP, which led to the lower risk 
category classification8. Based on these observations, it 
has been concluded that the main advantage of rP is 
to enable more precise staging of hrPC. further-
more, the duration of adjuvant Adt (in combination 
with eBrt) was significantly shorter among patients 
who were previously treated with rP when compared 
to those who received Adt plus eBrt as a first-line 
treatment for hrPC.
Oligometastatic prostate cancer
oligometastatic prostate cancer (oPC) has in-
creasingly been detected since the introduction of 
positron emission tomography (Pet), using ligands 
targeted at the prostate-specific membrane antigen 
(PSmA) or 18f-choline as radiotracers. Although 
there is no consensus for the exact definition of oPC, 
it is usually defined by the presence of £ 3 (or less than 
five) metastatic bone or lymph node lesions that could 
be treated with surgery or radiotherapy, without rapid 
dissemination to other sites.
There are at least four clinical scenarios of the oc-
currence of oPC: 1) initial presentation of oligometa-
static disease in the patient who has not been previ-
ously treated and is castration-naive (synchronous 
disease); 2) oligometastatic disease develops subse-
quently after keeping the cancer under control with 
surgical treatment or radiotherapy in the patient who 
is usually castration naive (metachronous disease); 3) 
recurrence of previously treated oligometastases in the 
patient who may be castration naive or not (oligo-re-
current disease); 4) systemic therapy of widely meta-
static prostatic cancer was successful considering the 
most of metastases, but a minority of metastatic le-
sions have advanced; the patients are castration resis-
tant (oligo-progressive disease).
recent multi-institutional study has been conduct-
ed on 113 patients with small pelvic lymph node or 
bone-only metastatic disease who were treated with 
cytoreductive radical prostatectomy and pelvic lymph-
adenectomy combined with Adt9. The treatment re-
sulted in 5-year overall survival in nearly 80% of pa-
tients, whereas a mean relapse-free survival was 6 years.
Surgical treatment of metachronous disease that is 
restricted to pelvic nodes without metastases in retro-
peritoneal lymph nodes includes salvage pelvic lymph 
node dissection (sPlnd), and treatment of other iso-
lated lesions involving metastasis-directed therapy 
(mdt). As reported by ost et al., Adt-free survival 
period was significantly longer in patients who under-
went mdt when compared to the surveillance group; 
additionally, among patients in the mdt group no 
grade 2 or greater toxicity was observed10. karnes et al. 
performed a retrospective study of patients who un-
derwent sPlnd for prostate cancer nodal recurrence 
after radical prostatectomy. no additional treatment 
was employed in 46.2% of patients. After 3 years of 
follow-up, 45.5% of patients remained biochemically 
recurrence-free; cancer specific survival was 92.5%, 
and systemic progression-free survival was 46.9%11. 
The results of recently reported, largest retrospective 
trial of 654 patients with nodal recurrent prostate can-
cer revealed that 75% of patients experienced no clini-
cal recurrence during the period of 1 year following 
sPlnd, whereas a median time to clinical recurrence 
was approximately 3 years12.
in conclusion, in recent times a significant progress 
in understanding the oligometastatic concept of pros-
tate cancer has been made. however, further efforts are 
needed to clarify different prognostic subgroups of 
oPC concerning clinical manifestations and prefera-
ble therapeutic approach.
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Sažetak
kirurŠko liJeČenJe kArCinomA ProStAte ViSokog riZikA  
i oligometAStAtSke BoleSti
I. Mokos, A. El Saleh, T. Kuliš, M. Topalović Grković, I. Bačak Kocman i Ž. Kaštelan
rak prostate ostaje najčešći uzrok smrtnosti od karcinoma u mnogim zemljama svijeta. Bolesnici s agresivnijom bolešću 
izloženi su većem riziku od neuspjeha lokalnog liječenja i smrti. liječenje visoko rizične lokalne bolesti najčešće uključuje 
radikalnu prostatektomiju, radioterapiju (eBrt) s androgenom deprivacijskom terapijom (Adt) ili eBrt plus brahitera-
piju (Bt) i Adt. kirurško liječenje karcinoma prostate visokog rizika (hrPC) je u porastu zbog svojih prednosti koje 
uključuju mogućnost izlječenja samo operacijom, točno određivanje stadija bolesti, uklanjanje dobroćudnog izvora PSA koji 
je čimbenik za određivanje buduće terapije, te mogućnost izbjegavanja toksičnosti dugotrajne primjene Adt-a. Čini se da je 
oligometastatska bolest posljednja barijera potencijalno izlječivog karcinoma prostate. radikalna prostatektomija u oligome-
tastatskom karcinomu prostate može značajno smanjiti rizik od lokalnih komplikacija, ali samo multimodalni pristup oda-
branoj skupini bolesnika može pružiti mogućnosti za potpuno uklanjanje tumora ili usporavanje njegovog napredovanja. 
kirurško liječenje oligometastatske bolesti najčešće je usmjereno na limfogeno širenje s disekcijom zahvaćenih zdjeličnih 
limfnih čvorova, a rjeđe može biti usmjereno na udaljene metastaze. Potrebna su daljnja prospektivna, randomizirana istraži-
vanja za definiranje uloge i vrijednosti terapije oligometastatskog karcinoma prostate.
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